Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Hemadsorption to Enhance Drug Elimination in Intoxications

NCT: NCT06922786 · RECRUITING

NCT IDNCT06922786
StatusRECRUITING
Start Date2025-05-01
Completion2029-01
SponsorUniversitair Ziekenhuis Brussel (OTHER)
First posted
Last updated

Brief Summary

In this trial the investigators assess the effectiveness of applying a hemadsorber (cytosorb®) in removing benzodiazepines or tricyclic antidepressants in intoxicated patients admitted to ICU with prolonged impaired consciousness. This is a one arm interventional investigation where a hemadsorption filter is applied in patients fulfilling inclusion criteria 8 hours after admission. Plasma titer of the neurodepressing drug will be collected sequentially both before and after start of hemadsorption to evaluate the speed of drug elimination before and after application of a hemadsorption filter. Pre- and post filter titers will be obtained to evaluate adsorbability and to evaluate time to saturation of the filter.

Frequently Asked Questions

What is Hemadsorption to Enhance Drug Elimination in Intoxications?

Hemadsorption to Enhance Drug Elimination in Intoxications is a clinical trial registered under NCT06922786. Current status: RECRUITING.

What is the status of NCT06922786?

The current status of NCT06922786 (Hemadsorption to Enhance Drug Elimination in Intoxications) is: RECRUITING.

When did Hemadsorption to Enhance Drug Elimination in Intoxications start?

Hemadsorption to Enhance Drug Elimination in Intoxications started on 2025-05-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.